Xvivo Perfusion AB (publ) (LON:0RKL)
London · Delayed Price · Currency is GBP · Price in SEK 184.69
-1.44 (-0.78%)
Dec 30, 2025, 5:13 PM BST
Xvivo Perfusion AB Market Cap
Xvivo Perfusion AB has a market cap or net worth of 474.66 million as of December 31, 2025. Its market cap has decreased by -54.38% in one year.
Market Cap
474.66M
Enterprise Value
462.11M
Revenue
64.23M
Ranking
n/a
PE Ratio
201.07
Stock Price
184.69
Market Cap Chart
Since October 8, 2012, Xvivo Perfusion AB's market cap has increased from 34.98M to 474.66M, an increase of 1,256.97%. That is a compound annual growth rate of 21.78%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Dec 30, 2025 | 474.66M | -57.41% |
| Dec 30, 2024 | 1.11B | 37.94% |
| Dec 29, 2023 | 807.93M | 85.88% |
| Dec 30, 2022 | 434.66M | -35.41% |
| Dec 30, 2021 | 672.92M | -16.86% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| AstraZeneca | 213.19B |
| GSK plc | 73.15B |
| Haleon | 33.22B |
| Smith & Nephew | 10.43B |
| Convatec Group | 4.74B |
| Hikma Pharmaceuticals | 3.40B |
| Genus | 1.73B |
| HUTCHMED (China) | 1.71B |